RODMAN&RENSHAW upgraded shares of TuHURA Biosciences (NASDAQ:HURA – Free Report) to a strong-buy rating in a research note issued to investors on Thursday,Zacks.com reports.
Several other brokerages also recently issued reports on HURA. Rodman & Renshaw started coverage on shares of TuHURA Biosciences in a report on Thursday. They set a “buy” rating and a $11.00 price target for the company. Maxim Group initiated coverage on shares of TuHURA Biosciences in a research report on Tuesday, November 5th. They issued a “buy” rating and a $15.00 target price for the company.
Get Our Latest Stock Report on TuHURA Biosciences
TuHURA Biosciences Stock Up 12.0 %
TuHURA Biosciences Company Profile
TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Featured Stories
- Five stocks we like better than TuHURA Biosciences
- Where to Find Earnings Call Transcripts
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- 3 Warren Buffett Stocks to Buy Now
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- Canadian Penny Stocks: Can They Make You Rich?
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
